FDA approves first cell-based gene therapy for rare, devastating skin disorder – but it comes with a huge price tag
(NaturalNews) The FDA approved Zevaskyn, the first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare and painful genetic dis...
 | (NaturalNews) The FDA approved Zevaskyn, the first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare and painful genetic dis... |
